NO20021441L - Antistoff-fargestoffkonjugater mot angiogenesemålstrukturer for intraoperativ presentasjon av tumorperiferier - Google Patents

Antistoff-fargestoffkonjugater mot angiogenesemålstrukturer for intraoperativ presentasjon av tumorperiferier

Info

Publication number
NO20021441L
NO20021441L NO20021441A NO20021441A NO20021441L NO 20021441 L NO20021441 L NO 20021441L NO 20021441 A NO20021441 A NO 20021441A NO 20021441 A NO20021441 A NO 20021441A NO 20021441 L NO20021441 L NO 20021441L
Authority
NO
Norway
Prior art keywords
antibody
dye conjugates
target structures
intraoperative
presentation
Prior art date
Application number
NO20021441A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021441D0 (no
Inventor
Michael Schirner
Kai Licha
Ludger Dinkelborg
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7924318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20021441(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20021441D0 publication Critical patent/NO20021441D0/no
Publication of NO20021441L publication Critical patent/NO20021441L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20021441A 1999-09-24 2002-03-22 Antistoff-fargestoffkonjugater mot angiogenesemålstrukturer for intraoperativ presentasjon av tumorperiferier NO20021441L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19947559A DE19947559A1 (de) 1999-09-24 1999-09-24 Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
PCT/EP2000/008121 WO2001023005A1 (de) 1999-09-24 2000-08-19 Antikörper-farbstoffkonjugate gegen zielstrukturen der angiogenese zur intraoperativen tumorranddarstellung

Publications (2)

Publication Number Publication Date
NO20021441D0 NO20021441D0 (no) 2002-03-22
NO20021441L true NO20021441L (no) 2002-05-15

Family

ID=7924318

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021441A NO20021441L (no) 1999-09-24 2002-03-22 Antistoff-fargestoffkonjugater mot angiogenesemålstrukturer for intraoperativ presentasjon av tumorperiferier

Country Status (23)

Country Link
EP (2) EP1214099A1 (xx)
JP (1) JP2003510294A (xx)
KR (2) KR20070087232A (xx)
CN (1) CN1269530C (xx)
AU (1) AU779026B2 (xx)
BG (1) BG65682B1 (xx)
BR (1) BR0014192A (xx)
CA (1) CA2385593A1 (xx)
CZ (1) CZ2002991A3 (xx)
DE (1) DE19947559A1 (xx)
EE (1) EE05176B1 (xx)
HK (1) HK1050491A1 (xx)
HU (1) HUP0202625A2 (xx)
IL (2) IL148405A0 (xx)
MX (1) MXPA02002639A (xx)
NO (1) NO20021441L (xx)
NZ (1) NZ517944A (xx)
RO (1) RO121598B1 (xx)
RU (1) RU2002109237A (xx)
SK (1) SK3972002A3 (xx)
WO (1) WO2001023005A1 (xx)
YU (1) YU20702A (xx)
ZA (1) ZA200203225B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
US6440389B1 (en) * 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
AT413487B (de) 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
NO20034351D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av endometrose
DE602004009169D1 (de) * 2004-07-22 2007-11-08 Bayer Schering Pharma Ag Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
AU2010239272B2 (en) * 2009-04-21 2015-09-17 The University Of Utah Research Foundation Light-emitting dye for intraoperative imaging or sentinel lymph node biopsy
EP3493855A4 (en) * 2016-08-02 2020-04-01 ISI Life Sciences, Inc. METHOD FOR DETECTION OF CANCER CELLS.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341223A (en) * 1981-02-04 1982-07-27 Lutz Lauralee A Fluoresceable composition and method of determining fluid flow
EP0771216B9 (en) * 1994-07-11 2003-01-02 The Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of tumoral vasculature
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis

Also Published As

Publication number Publication date
NZ517944A (en) 2004-06-25
ZA200203225B (en) 2003-07-23
EP1532988A3 (de) 2008-09-17
EE05176B1 (et) 2009-06-15
KR20020039349A (ko) 2002-05-25
CN1269530C (zh) 2006-08-16
CA2385593A1 (en) 2001-04-05
PL354027A1 (en) 2003-12-15
CZ2002991A3 (cs) 2002-06-12
BG65682B1 (bg) 2009-06-30
EP1532988A2 (de) 2005-05-25
BG106528A (bg) 2002-12-29
RU2002109237A (ru) 2003-11-27
DE19947559A1 (de) 2001-04-19
BR0014192A (pt) 2002-05-21
NO20021441D0 (no) 2002-03-22
SK3972002A3 (en) 2002-09-10
JP2003510294A (ja) 2003-03-18
WO2001023005A1 (de) 2001-04-05
KR20070087232A (ko) 2007-08-27
AU779026B2 (en) 2005-01-06
IL148405A0 (en) 2002-09-12
HK1050491A1 (en) 2003-06-27
MXPA02002639A (es) 2002-07-30
KR100832937B1 (ko) 2008-05-27
EE200200152A (et) 2003-04-15
EP1214099A1 (de) 2002-06-19
IL148405A (en) 2009-06-15
HUP0202625A2 (en) 2002-12-28
CN1376074A (zh) 2002-10-23
AU6702600A (en) 2001-04-30
RO121598B1 (ro) 2007-12-28
YU20702A (sh) 2005-06-10

Similar Documents

Publication Publication Date Title
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
IS2468B (is) Aðferðir og milliefni til framleiðslu á efnasamböndum gegn krabbameini
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
NO20005632D0 (no) Antistoffer mot CD 23, derivater derav og deres terapeutiske anvendelse
IS6375A (is) Lyfjagjöf til öftrunar á blöðruhálskrabbameini
NO20021701L (no) Fremgangsmåte for fremstilling av et konjugat av polyglutamat og et terapeutisk middel
DK1200590T3 (da) C-type lectin-transmembran-antigen, der udtrykkes ved human prostatacancer, og anvendelser deraf
AU2002254482A1 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
NO20021441L (no) Antistoff-fargestoffkonjugater mot angiogenesemålstrukturer for intraoperativ presentasjon av tumorperiferier
WO2004004636A3 (en) Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002215904A1 (en) Compounds with a branched linker
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
HUP0301846A2 (hu) A CD25-kötż molekulák alkalmazása a gyomor-bél-rendszer gyulladásos betegségeinek kezelésében
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
SE0000597D0 (sv) Novel antibody
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2001296224A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU3282300A (en) Molecules for the treatment and diagnosis of tumors